NasdaqGM:WVEPharmaceuticals
Wave Life Sciences Faces Setback As WVE-007 Fails And Investor Exits
Wave Life Sciences' obesity candidate WVE-007 did not show meaningful improvement in recent clinical data.
Following the data release, institutional investor Exome Asset Management exited its entire position in NasdaqGM:WVE.
The setback affects Wave Life Sciences' obesity efforts and adds pressure to its broader development pipeline.
For investors watching NasdaqGM:WVE, this update comes in the context of a share price of $5.73 and a year-to-date return that is down 64.1%. The stock has...